Consolidated statement of changes in equity
January 1 – June 30
|
|
|
|
Attributable to shareholders of Sulzer Ltd |
|
|
|
|
||||||||||
millions of CHF |
|
|
Share capital |
|
Retained earnings |
|
Treasury shares |
|
Cash flow hedge reserve |
|
Currency translation adjustment |
|
Total |
|
Non-controlling interests |
|
Total equity |
|
Equity as of January 1, 2023 |
|
|
|
0.3 |
|
1’777.7 |
|
–42.9 |
|
–4.1 |
|
–706.7 |
|
1’024.3 |
|
4.4 |
|
1’028.6 |
Comprehensive income for the period: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
|
|
103.9 |
|
|
|
|
|
|
|
103.9 |
|
0.3 |
|
104.3 |
- Cash flow hedges, net of tax |
|
|
|
– |
|
|
|
– |
|
9.7 |
|
– |
|
9.7 |
|
|
|
9.7 |
- Remeasurements of defined benefit plans, net of tax |
|
|
|
– |
|
9.4 |
|
– |
|
– |
|
– |
|
9.4 |
|
|
|
9.4 |
- Equity investments at FVOCI – net change in fair value, net of tax |
|
|
|
– |
|
2.4 |
|
– |
|
– |
|
– |
|
2.4 |
|
|
|
2.4 |
- Currency translation differences |
|
|
|
– |
|
|
|
– |
|
– |
|
–66.6 |
|
–66.6 |
|
–0.4 |
|
–67.1 |
Other comprehensive income |
|
|
|
– |
|
11.8 |
|
– |
|
9.7 |
|
–66.6 |
|
–45.1 |
|
–0.4 |
|
–45.6 |
Total comprehensive income for the period |
|
|
|
– |
|
115.8 |
|
– |
|
9.7 |
|
–66.6 |
|
58.8 |
|
–0.1 |
|
58.7 |
Transactions with owners of the company: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition of non-controlling interests without a change in control |
|
|
|
|
–22.4 |
|
– |
|
– |
|
0.0 |
|
–22.4 |
|
–0.4 |
|
–22.8 |
|
Contribution from medmix |
|
|
– |
|
0.3 |
|
– |
|
– |
|
– |
|
0.3 |
|
– |
|
0.3 |
|
Allocation of treasury shares to share plan participants |
|
|
|
– |
|
–26.3 |
|
26.3 |
|
– |
|
– |
|
– |
|
– |
|
– |
Purchase of treasury shares |
|
|
|
– |
|
– |
|
–9.4 |
|
– |
|
– |
|
–9.4 |
|
– |
|
–9.4 |
Share-based payments |
|
|
|
– |
|
6.1 |
|
– |
|
– |
|
– |
|
6.1 |
|
– |
|
6.1 |
Dividends |
|
|
– |
|
–118.9 |
|
– |
|
– |
|
– |
|
–118.9 |
|
–0.1 |
|
–119.0 |
|
Equity as of June 30, 2023 |
|
|
|
0.3 |
|
1’732.2 |
|
–25.9 |
|
5.6 |
|
–773.4 |
|
938.8 |
|
3.8 |
|
942.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity as of January 1, 2024 |
|
|
|
0.3 |
|
1’979.5 |
|
–36.7 |
|
4.2 |
|
–852.0 |
|
1’095.4 |
|
3.2 |
|
1’098.6 |
Comprehensive income for the period: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
|
|
116.6 |
|
|
|
|
|
|
|
116.6 |
|
0.8 |
|
117.4 |
- Cash flow hedges, net of tax |
|
|
|
– |
|
– |
|
– |
|
–11.3 |
|
– |
|
–11.3 |
|
– |
|
–11.3 |
- Remeasurements of defined benefit plans, net of tax |
|
|
|
– |
|
21.0 |
|
– |
|
– |
|
– |
|
21.0 |
|
– |
|
21.0 |
- Equity investments at FVOCI – net change in fair value, net of tax |
|
|
|
– |
|
–2.7 |
|
– |
|
– |
|
– |
|
–2.7 |
|
– |
|
–2.7 |
- Currency translation differences |
|
|
|
– |
|
– |
|
– |
|
– |
|
61.1 |
|
61.1 |
|
0.4 |
|
61.5 |
Other comprehensive income |
|
|
|
– |
|
18.3 |
|
– |
|
–11.3 |
|
61.1 |
|
68.1 |
|
0.4 |
|
68.5 |
Total comprehensive income for the period |
|
|
|
– |
|
134.9 |
|
– |
|
–11.3 |
|
61.1 |
|
184.7 |
|
1.2 |
|
185.9 |
Transactions with owners of the company: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Changes in non-controlling interests |
|
|
|
– |
|
–3.2 |
|
– |
|
– |
|
– |
|
–3.2 |
|
3.2 |
|
0.0 |
Contribution from medmix |
|
|
– |
|
0.1 |
|
– |
|
– |
|
– |
|
0.1 |
|
|
|
0.1 |
|
Allocation of treasury shares to share plan participants |
|
|
|
– |
|
–18.1 |
|
18.1 |
|
– |
|
– |
|
– |
|
|
|
– |
Purchase of treasury shares |
|
|
– |
|
– |
|
–15.7 |
|
– |
|
– |
|
–15.7 |
|
|
|
–15.7 |
|
Share-based payments |
|
|
|
– |
|
6.6 |
|
– |
|
– |
|
– |
|
6.6 |
|
|
|
6.6 |
Dividends |
|
|
– |
|
–127.3 |
|
– |
|
– |
|
– |
|
–127.3 |
|
–0.1 |
|
–127.3 |
|
Equity as of June 30, 2024 |
|
|
|
0.3 |
|
1’972.6 |
|
–34.3 |
|
–7.1 |
|
–790.8 |
|
1’140.7 |
|
7.5 |
|
1’148.2 |